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Abstract 
　　In 2 premature infants with patent ductus arteriosus (PDA), indomethacin was discontinued because of renal 
failure in one and repeated re-opening of the ductus arteriosus in the other. Combined administration of low 
doses of dexamethasone and indomethacin resulted in complete closure of the PDA in both infants without serious 
side effects. This method of combined therapy may be an option in the medical management of PDA before 
considering surgical treatment, especially in premature infants when the PDA fails to close with indomethacin 
alone or when there are adverse side effects of indomethacin.
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gestation by emergency cesarean section with a birth 
weight of 1,520 g. The Apgar scores were 4 and 6 at 1 
and 5 minutes, respectively. She received oxygen ther-
apy with FiO2 0.3 because of tachypnea. Her respira-
tory condition improved gradually, but the condition 
showed exacerbation again at the age of 3 days. She 
was transferred to the neonatal intensive care unit of our 
university hospital 2 days later. A grade 2/6 diastolic 
murmur was present and the chest X-ray showed a car-
diothoracic ratio of 67% upon admission. A large PDA, 
mitral regurgitation and tricuspid regurgitation were 
diagnosed by echocardiography (Fig. 1-A,B). Fluids 
were restricted and diuretic therapy was given. She was 
treated with indomethacin at a dose of 0.2 mg/kg at 7 
days of age and 0.25 mg/kg at 8 days. Slight constric-
tion of the PDA was confirmed by echocardiography, but 
indomethacin was contraindicated because of occult 
blood in the urine and elevated serum creatinine to 2.5 
mg/dl. The diastolic murmur and cardiomegaly on the 
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Introduction
　Indomethacin has been widely used to close patent 
ductus arteriosus (PDA) in premature infants. The dose 
administered in Japan in general depends upon age : 0.1-
0.2 mg/kg within the first 2 days of life ; 0.2-0.25 mg/kg 
from day 2 to day 7 ; 0.25 mg/kg after day 7. When 
these doses are administered at intervals from 12-24 
hours, indomethacin is usually effective in closing the 
PDA ; however, there are some adverse side effects, 
such as renal failure, active bleeding and thrombocytope-
nia, but the PDA may fail to close in some cases (1). To 
find a better treatment for PDA, we tried combination 
therapy with low doses of both dexamethasone and indo-
methacin in two premature infants. 
 Case report
Case 1
　A female infant was born at 34 weeks and 5 days of 
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chest X-ray film persisted. After informed consent was 
obtained, administration of low doses of dexamethasone 
(0.3 mg/kg/day×3, 0.2 mg/ke/day×3, 0.1 mg/kg/day×3 ; 
divided into two daily doses) was given from 9 to 18 
days of age. Since we confirmed the constriction of 
PDA at 12 days of age (Fig. 2-A,B), we decided to start 
the combined therapy. After the serum creatinine 
decreased to 1.05 mg/dl, low doses of indomethacin 
(0.1 mg/kg×5, at 12 hour intervals) were given from 12 
to 15 days of age. During the course of therapy, serum 
creatinine did not exceed 1.0 mg/dl after administraion of 
indomethacin (0.1 mg/kg) and no other severe side 
effects of indomethacin appeared. 
Case 2
　A female infant was born at 27 weeks and 2 days of 
gestation by emergency cesarean section because of pre-
mature rupture of membranes and threatened premature 
birth. Her birth weight was 1,163 g and the Apgar score 
was 6 at 1 minute. She received mechanical ventilation 
but no respiratory distress syndrome (RDS) was detected.　
Chorioamnionitis was confirmed by histological exami-
nation. Laboratory examinations revealed plasma 
immunoglobulin M (IgM) of 59.0 mg/dl upon admis-
sion. The chest X-ray film showed diffuse and streaky 
infiltrate with a small cystic area from 2 days after 
birth. We suspected Wilson-Mikity syndrome from the 
clinical symptoms and laboratory findings. The PDA 
was closed as confirmed by echocardiography at 4 
days. On day 20 of life, the chest X-ray showed atelec-
tasis of the right upper lobe with infection sign, C-reac-
tive protein 3.6 mg/dl, and a heart murmur appeared.　
PDA was diagnosed by echocardiography and she was 
treated successfully with indomethacin (0.25 mg/
kg×1). At 24 days of age, the PDA re-opened and she 
was given indomethacin (0.25 mg/kg×2) and the PDA 
closed. At 28 days of age, the heart murmur was pres-
ent again, PDA was diagnosed by echocardiography, and 
indomethacin (0.25 mg/kg×3) was given, followed by 
disappearance of the murmur. However, the PDA 
opened again at 35 days of age. After informed consent 
was obtained, combined administration of dexametha-
Figure 1 A large PDA (A), mitral regurgitation and tricuspid regurgitation (B) were diagnosed at 5 days of age by echocardiography
Figure 2 The constriction of PDA was observed at 12 days of age by echocardiography (A, B)
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sone and indomethacin was given intravenously. Dexa-
methasone (0.3 mg/kg/day×3, 0.2 mg/kg/day×3, 0.1 mg/
kg/day×3 ; divided into two daily doses) was started 
from 37 days of age and indomethacin (0.2 mg/kg×5) 
was given from 39 days of age. The PDA was closed, 
as confirmed by echocardiography, at 44 days and she 
was successfully extubated the following day. The PDA 
did not re-open after that time. Transient oliguria and 
hypertension were recognized during the course but there 
were no severe side effects of indomethacin such as 
active bleeding. 
Discussion
　Steroid hormones constricted the fetal PDA dose-
dependently in fetal rats (2). Although the mechanism 
of steroid hormones in constricting the PDA is not com-
pletely clear, Clyman et al showed that transplacental 
hydrocortisone decreased the sensitivity of the ductal 
muscle to the dilative effects of prostaglandin (PG) E2 in 
fetal lambs (3). Flower et al and Kuehl et al also 
reported that steroids could possibly have a direct effect 
on the PDA, leading to closure through interference with 
PG synthesis (4, 5). Clinically, Heyman et al reported 4 
cases showing a temporal relationship between closure of 
the PDA and treatment with postnatal dexamethasone 
(0.4-0.5 mg/kg/day) given to preterm infants less than 
1,000 g at birth (6). Furthermore, Morales et al demon-
strated that in dexamethasone therapy the most common 
dosage regimen is 0.5 mg/kg/day divided into two daily 
doses tapered over a period of 12 days for surfactant-
treated infants reduced the incidence of clinically detect-
able PDA and of bronchopulmonary dysplasia in prema-
ture infants as compared with infants treated with 
surfactant alone (7). They suggested that the clinical 
mechanism of PDA closure in dexamethasone-treated 
infants may in part have been related to diuresis. On 
the other hand, Watterberg et al showed that lower serum 
cortisol concentrations in very low birth weight infants 
correlated with the presence of PDA (8). This means 
that increased endogenous cortisol production in prema-
ture infant may promote ductal constriction, resulting in 
a decreased incidence of PDA. 
　We demonstrated greater constriction of the fetal PDA 
with the combined administration of dexamethasone and 
indomethacin than with dexamethasone or indomethacin 
alone in preterm and near-term fetal rats (9). In this 
clinical report, 2 cases showed the usefulness of com-
bined therapy with dexamethasone and indometha-
cin. In case 1, the PDA was closed completely in com-
bination with smaller doses of both dexamethasone and 
indomethacin without renal failure. In this infant, indo-
methacin was contraindicated after administration of two 
standard doses because of renal failure with occult blood 
in the urine and elevated serum creatinine. We tried to 
administer a low dose of dexamethasone before having 
to consider surgical treatment, and the constriction of 
PDA was confirmed. We decided to start combined 
therapy. In case 2, combined administration of smaller 
doses of both dexamethasone and indomethacin showed 
greater constriction of the PDA in a premature infant in 
whom indomethacin therapy was discontinued because 
of repeated PDA re-opening. In these 2 premature 
infants, combined administration of smaller doses of both 
dexamethasone and indomethacin showed synergistic 
constriction of the PDA. 
　Recently, there is increasing concern that early and 
moderately-early postnatal corticosteroid therapy may 
have adverse effects on neurodevelopment (10). Stark 
et al showed that gastrointestinal perforations were 
increased in infants with extremely low birth weight < 
1,000 g when dexamethasone was given with indometha-
cin within 24 hours of birth (11). Since prostaglandins 
play an important role in maintaining gastrointestinal 
integrity, inhibition of prostaglandin synthesis by cortico-
steroid and indomethacin may account for the gastroin-
testinal perforation. Therefore, administration of ste-
roids under these conditions should be done carefully 
with reduced doses that are gradually tapered. 
　We suggest that combined therapy with smaller doses 
of both dexamethasone and indomethacin may be useful 
in constrictiong PDA when indomethacin alone is contra-
indicated due to side effects such as renal failure, active 
bleeding and thrombocytopenia. This combined therapy 
may also be useful when indomethacin alone fails to 
close the PDA, especially in premature infants weighing 
more than 1,000 g at birth, except in the early treatment 
of PDA in some cases before considering surgical treat-
ment. Moreover, since hydrocortisone has less side 
effects than dexamethasone, it also might be useful for 
combined therapy with indomethacin. Further clinical 
studies are necessary to evaluate the long-term risks and 
benefits of combined therapy in neonates. 
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早産児動脈管開存症におけるデキサメタゾン、 
インドメタシン併用療法の 2 症例
石　井　宏　樹　　　高　見　　　剛　　　佐　藤　　　智 
近　藤　　　敦　　　春　原　大　介　　　星　加　明　德
東京医科大学小児科学講座
　腎障害と繰り返す再発により、動脈管開存症（PDA）に対するインドメサシン治療継続が困難になった早産児 2
症例に対して、低用量のデキサメサゾンとインドメサシンの併用療法を行い、2 例とも重篤な合併症なく PDA の完
全閉鎖が得られた。この併用療法は、特にインドメサシン単独投与で閉鎖が得られない症例や副作用により治療継
続が困難となった早産児に対して、外科的手術を考慮する前の内科的治療としての選択肢の一つになると考えられ
た。
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